# Adela

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adela

- Industry: Healthcare
- Headquarters: Foster City, US
- Website: www.adelabio.com
- Total disclosed funding: $60M
- Latest round: Series A (Jun 23, 2021)
- Investors on record: 5

## About

Based in Toronto, Canada, and founded in 2020, Adela, formerly known as DNAMx, Inc., provides a diagnosis of cancer. The company was co-founded by Daniel Carvalho and Scott Bratman. In June 2021, the company raised its latest Series A funding led by F-Prime Capital. 

The company develops a methylation enrichment technology that detects signals of early disease with high sensitivity through efficient mining of the entire methylome. The company's technology is primarily focused on the detection of diseases like cancer and other high morbidity and mortality conditions.

The company's revenue is generated by the sales of its methylation enrichment technology to its target market that includes various medical institutions.

The company plans to develop its technology to use across the entire cancer continuum for detection, diagnosis, and management of a disease. The company also plans to advance its technology towards commercialization.

## Funding rounds

- Series A, Jun 23, 2021, $60M — OrbiMed Advisors, F-Prime Capital, Decheng Capital, Deerfield Management, RA Capital Management

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A